Furthermore, insulin sensitivity restoration, insulin, and IGF therapy have been suggested to improve cognitive performance and memory function in healthy humans, individuals with mild cognitive impairment (MCI), and AD patients (Reger et al., 2008; Bomfim et al., 2012; Bedse et al., 2015), protect neurons from amyloid-induced toxicity in primary cell culture studies (Mattson, 1997), and prevent tau hyperphosphorylation in animal models (Deng et al., 2009; Chen et al., 2013). Here, MAPT is linked to Alzheimer disease.